133081-26-2

Basic information

• Product Name: SUCCINIMIDYL 6-BOC-HYDRAZINONICOTINATE
• Synonyms: SUCCINIMIDYL-N-BOC-HYNIC;SUCCINIMIDYL 6-BOC-HYDRAZINONICOTINATE;N'-(5-[2-(2,5-DIOXO-PYRROLIDIN-1-YLOXY)-ACETYL]-PYRIDIN-2-YL)-HYDRAZINECARBOXYLIC ACID TERT-BUTYL ESTER;6-BOC-HYDRAZINOPYRIDINE-3-NHS;HYDRAZINECARBOXYLIC ACID, 2-[5-[[(2,5-DIOXO-1-PYRROLIDINYL)OXY]CARBONYL]-2-PYRIDINYL]-, 1,1-DIMETHYLETHYL ESTER;6-Boc-hydrazinopyridine-3-NHS, Succinimidyl-N-Boc-Hynic, N''-{5-[2-(2,5-Dioxo-pyrrolidin-1-yloxy)-acetyl]-pyridin-2-yl}-hydrazinecarboxylic acid tert-butyl ester;2,5-Dioxopyrrolidin-1-yl 6-(2-(tert-butoxycarbonyl)hydrazinyl)nicotinate
• CAS NO: 133081-26-2
• Molecular Formula: C₁₅H₁₈N₄O₆
• Molecular Weight: 350.33
• Mol File: 133081-26-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 168-171 °C
• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.47±0.43(Predicted)
• CAS DataBase Reference: SUCCINIMIDYL 6-BOC-HYDRAZINONICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: SUCCINIMIDYL 6-BOC-HYDRAZINONICOTINATE(133081-26-2)
• EPA Substance Registry System: SUCCINIMIDYL 6-BOC-HYDRAZINONICOTINATE(133081-26-2)

Safety Data

• Hazardous Substances Data: 133081-26-2(Hazardous Substances Data)

Usage

Chemical Properties

Colourless crystals

Upstream product

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 123-56-8 Succinimide 
• 133081-25-1 6-({[(tert-butoxy)carbonyl]amino}amino)pyridine-3-carboxylic acid 
• 133081-24-0 6-hydrazinylnicotinic acid 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 

Downstream Products

• 959149-84-9 C₈₇H₁₃₇N₂₃O₂₂ 
• 1357390-43-2 N'-(5-{2-[3,5-bis-(2-fluorobenzylidene)-4-oxopiperidin-1-yl]ethylcarbamoyl}pyridin-2-yl)hydrazinecarboxylic acid tert-butyl ester 
• 1357390-44-3 N-{2-[3,5-bis-(2-fluorobenzylidene)-4-oxo-piperidin-1-yl]-ethyl}-6-hydrazinonicotinamide 
• 133081-27-3 succinimidyl 6-hydrazinopyridine-3-carboxylate hydrochloride 
• 1160707-23-2 2-[2'-(6-N₂-Boc-hydrazinonicotinamido-propoxy)-4'-amino]phenyl-1,3-benzothiazole 
• 182410-68-0 Boc-Hynic-(D)-Phe-Cys(Acm)-Phe-(D)-Trp-Lys(Boc)-Thr-NHNH₂ 
• 182410-67-9 Boc-Hynic-(D)-Phe-Cys(Acm)-Phe-(D)-Trp-Lys(Boc)-Thr-OMe 
• 945034-48-0 C₄₂H₄₆N₆O₉ 
• 182410-65-7 (R)-3-(Acetylamino-methylsulfanyl)-2-((R)-2-{[6-(N'-tert-butoxycarbonyl-hydrazino)-pyridine-3-carbonyl]-amino}-3-phenyl-propionylamino)-propionic acid 

Relevant articles and documents

PSMA inhibitor, application thereof and PSMA-targeting nuclide imaging reagent

The invention belongs to the technical field of biological medicines, and particularly relates to a PSMA inhibitor, an application thereof and a PSMA-targeting nuclide imaging reagent. The PSMA inhibitor has a structure as shown in a formula I. The PSMA-targeting nuclide imaging reagent prepared by adopting EDDA as a co-ligand has good PSMA targeting property and affinity; high stability is realized in normal saline and mouse serum; meanwhile, the cell uptake amount is relatively high, and the metabolic performance is good. Therefore, the inhibitor has a good clinical application prospect in tumor imaging of targeted PSMA.

Syntheses and biological evaluation of 99mTc-HYNIC-fatty acid complexes for myocardial imaging

The aim of the present study is to identify a 99mTc-labeled fatty acid tracer which could be a possible substitute of the widely used 123I-labeled fatty acids in studying myocardial metabolism and in detection of myocardial abnormalities in high-risk patients. The relevance of the study stems from the fact that in terms of wider applicability, a 99mTc-tracer is expected to be more advantageous compared to that of a 123I-based one. Two fatty acid (FA)-hydrazinopyridine-3-carboxylic acid (HYNIC) conjugates (11C-FA-HYNIC and 12C-FA-HYNIC) were synthesized and radiolabeled with 99mTc using two different co-ligands system viz. tricine/ethylenediamine diacetic acid (EDDA), and tricine/trisodium triphenylphosphine-3,3′,3′′-trisulfonate (TPPTS), to yield four radiolabeled complexes. While all four 99mTc-HYNIC-complexes showed uptake in the myocardium, 12C-FA-HYNIC-99mTc-EDDA complex showed higher uptake and retention in myocardium compared to other complexes. In general, uptake of the 99mTc-complexes in non-target organs was lower than that of 125I-iodophenyl pentadecanoic acid (IPPA). The 12C-FA-HYNIC-99mTc-EDDA complex, additionally exhibited lower liver accumulation compared to that of 125I-IPPA. Though these features were favorable for cardiac imaging, the heart-to-blood ratio of the complexes were low (99mTc-EDDA complex in Swiss mouse showed delineation of its myocardium from proximal non-target organs. The results merit further screening of synthetically modified 99mTc-HYNIC fatty acids for myocardial imaging.

Synthesis of radiolabeled cytarabine conjugates

N4-Modified, novel Ara-C conjugate capable of radiolabeling with gamma ray-emitting (99mTc) as well as positron emitting (18F) radionuclides, that is, N4-hydrazine derivative was synthesized. The radiolabeling of N4-(hydrazinonicotin